Authors: Sanya Sukduang, William B. Raich Ph.D., Jonathan R. Davies Ph.D., Aaron Gleaton Clay
Editor: Aaron Gleaton Clay
On July 21, 2015, the Federal Circuit issued a divided decision in Amgen Inc. v. Sandoz Inc., No. 15-1499 (Fed. Cir. July 21, 2015), interpreting two provisions of the Biologics Price Competition and Innovation Act (“BPCIA”). The Federal Circuit decided two issues: 1) whether, as Amgen contends, the BPCIA requires Sandoz, and other biosimilar applicants, to provide a complete copy of their biosimilar application and manufacturing information within twenty days after the FDA accepts the application, and 2) whether Sandoz’s 180-day notice of commercial marketing was premature, as it was provided before the FDA approved and licensed Zarxio® (filgrastim-sndz), Sandoz’s biosimilar to Amgen’s Neupogen® product (filgrastim). These issues provided the Federal Circuit with its first real opportunity to substantively interpret the provisions of the BPCIA.
For a more detailed summary of this case, check out Finnegan’s recent IP Update.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.